文献速递MDS 与骨髓增殖性肿瘤白血病

2017年修订版WHO慢性粒单核细胞白血病分类的验证

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
PubMed 文献 · Blood Adv · 2018-01-01

本研究利用单中心629例慢性粒单核细胞白血病(CMML)患者队列,评估2017年WHO修订分类中新亚型的预后价值。MP-CMML患者总生存期显著短于MDS-CMML患者(P<.0001;风险比0.53,95%CI 0.42-0.65),中位至急性髓系白血病转化时间分别为15.2个月与22.0个月(P<.0001)。CMML-0与CMML-1/2亚组间总生存期差异边缘显著(P=.0552),基于原始细胞的分类与无急性髓系白血病生存无关。

要点

  • MP-CMML患者总生存期显著短于MDS-CMML患者,风险比0.53(95%CI 0.42-0.65)。
  • MP-CMML中位至AML转化时间15.2个月,MDS-CMML为22.0个月(P<.0001)。
  • 基于原始细胞的三层分类未改善CPSS预后效能,在CMML-0与CMML-1/2间总生存差异边缘(P=.0552)。

核心结论

  • 数据支持将MP-CMML和MDS-CMML亚型纳入2017年WHO修订版。
  • 三层基于原始细胞的分类系统在本研究中未获良好支持,尽管在MP-CMML中有一定效用。

研究设计与样本

  • 单中心CMML患者队列研究,样本量n=629。
  • 按CMML特异性预后评分系统(CPSS)和MD Anderson预后评分系统进行风险分层。

主要发现

  • MP-CMML患者总生存期显著短于MDS-CMML患者(P<.0001;风险比0.53,95%CI 0.42-0.65)。
  • MP-CMML患者中位至AML转化时间显著短于MDS-CMML患者(P<.0001;15.2个月 vs 22.0个月)。
  • CMML-0组包含36.4%较高危CPSS类别患者和11.2%高危细胞遗传学患者。
  • 在初治患者(n=499)中,CMML-0与CMML-1/2亚组间总生存期差异边缘显著(P=.0552)。
  • 2017年WHO基于原始细胞的分类与无AML生存无关;将其纳入改良CPSS方案效果中性,未改善预后强度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification of chronic myelomonocytic leukemia (CMML): (1) a 3-tiered blast-based scheme including a novel "CMML-0" category replacing a 2-tiered system in place since 2001 and (2) 2 CMML subtypes, myelodysplastic (MDS-CMML) and myeloproliferative (MP-CMML), based on a white blood cell count cutoff of 13 × 109/L. The clinical utility of this subclassification scheme, particularly the expansion of blast-based subgroups, has not been validated. In this study, a large single-institution CMML patient cohort (n = 629) was used to assess the prognostic impact of the newly proposed categories. Patients were risk stratified according to the CMML-specific Prognostic Scoring System (CPSS) and the MD Anderson Prognostic Scoring System. MP-CMML patients had significantly shorter overall survival (OS; P < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (P < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients. The CMML-0 group included 36.4% patients with higher risk CPSS categories and 11.2% of patients with high-risk cytogenetics. Among treatment-naïve patients (n = 499), there was a marginal difference in OS between the CMML-0 and CMML-12017 subgroups (P = .0552). The WHO 2017 blast-based categories were not associated with AML-free survival. Incorporation of the WHO 2017 blast-based subgroups in a modified CPSS scheme had a neutral effect and did not improve its prognostic strength. Our data support the inclusion of MP-CMML and MDS-CMML subtypes in the WHO 2017 revision. Although of some utility in MP-CMML, the 3-tiered blast-based system is not well supported in this study.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Loghavi S, Sui D, Wei P, et al. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018. PMID: 30054307. doi:10.1182/bloodadvances.2018019224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。